DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1028 Eisen HJ, Tuzcu EM, Dorent R, et al., for the RAD B253 Study
Group. Everolimus for the prevention of allograft rejection and
vasculopathy in cardiac-transplant recipients. N Engl J Med,
2003, 349:847–858.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure
to calcineurin inhibitors in renal transplantation. N Engl
J Med, 2007, 357:2562–2575.
Emamaullee J, Toso C, Merani S, Shapiro AM. Costimulatory
blockade with belatacept in clinical and experimental transplantation-a
review. Expert Opin Biol Ther, 2009, 9:789–796.
Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin
inhibitor-sparing regimens in solid organ transplantation:
Focus on improving renal function and nephrotoxicity. Clin
Transplant, 2008, 22:1–15.
Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered
aglycosylated humanized CD3 antibody in renal transplant
rejection. Transplantation, 1999, 68:1632–1637.
Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel
immunosuppressant isolated from Streptomyces tsukubaensis.
Transplant Proc, 1987, 19:4–8.
Groth CG, Backman L, Morales JM, et al. Sirolimus
(rapamycin)-based therapy in human renal transplantation:
Similar efficacy and different toxicity compared with
cyclosporine. Sirolimus European Renal Transplant Study
Group. Transplantation, 1999, 67:1036–1042.
Hafler JP, Maier LM, Cooper JD, et al., for the International
Multiple Sclerosis Genetics Consortium (IMSGC). CD226
Gly307Ser association with multiple autoimmune diseases.
Genes Immun, 2008 Oct 30 [Epub ahead of print].
Herbelin A, Chatenoud L, Roux-Lombard P, et al. In vivo soluble
tumor necrosis factor receptor release in OKT3-treated
patients. Differential regulation of TNF-sR55 and TNF-sR75.
Transplantation, 1995, 59:1470–1475.
Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal
antibody in new-onset type 1 diabetes mellitus. N Engl J Med,
2002, 346:1692–1698.
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study
of polyomavirus type BK replication and nephropathy in renaltransplant
recipients. N Engl J Med, 2002, 347:488–496.
Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in
combination with rapamycin to eliminate cyclosporine treatment
during the induction phase of immunosuppression.
Transplantation, 1999, 68:701–704.
Hong JC, Kahan BD. Immunosuppressive agents in organ transplantation:
Past, present, and future. Semin Nephrol, 2000,
20:108–125.
Howard RJ, Condie RM, Sutherland DE, et al. The use of antilymphoblast
globulin in the treatment of renal allograft rejection:
A double-blind, randomized study. Transplantation,
1997, 24:419–423.
International Multiple Sclerosis Genetic Consortium, Hafler DA,
Compston A, et al. Risk alleles for multiple sclerosis identified
by a genomewide study. N Engl J Med, 2007, 357:851–862.
International Multiple Sclerosis Genetics Consortium (IMSGC).
Refining genetic associations in multiple sclerosis. Lancet
Neurol, 2008, 7:567–569.
Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces
the incidence of acute rejection episodes despite lower
cyclosporine doses in Caucasian recipients of mismatched primary
renal allografts: A phase II trial. Rapamune Study Group.
Transplantation, 1999, 68:1526–1532.
SECTION IV
INFLAMMATION, IMMUNOMODULATION, AND HEMATOPOIESIS
Khanna A, Li B, Stenzel KH, Suthanthiran M. Regulation of new
DNA synthesis in mammalian cells by cyclosporine.
Demonstration of a transforming growth factor beta-dependent
mechanism of inhibition of cell growth. Transplantation, 1994,
57:577–582.
Khoury S, Sayegh MH, Turka LA. Blocking costimulatory signals
to induce transplantation tolerance and prevent autoimmune
disease. Int Rev Immunol, 1999, 18:185–199.
Kohler G, Milstein C. Continuous cultures of fused cells secreting
antibody of predefined specificity. Nature, 1975, 256:495–497.
Kovarik JM, Kahan BD, Rajagopalan PR, et al. Population pharmacokinetics
and exposure-response relationships for basiliximab
in kidney transplantation. The U.S. Simulect Renal
Transplant Study Group. Transplantation, 1999, 68:1288–1294.
Krensky AM, Clayberger C. Prospects for induction of tolerance
in renal transplantation. Pediatr Nephrol, 1994, 8:772–779.
Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al.
Canakinumab in CAPS Study Group. Use of canakinumab in
the cryopyrin-associated periodic syndrome. N Eng J Med,
2009, 360:2416–2425.
Lawen J, Davies E, Morad F, et al. Basiliximab (Simulect) is safe
and effective in combination with triple therapy of Neoral, steroids
and CellCept in renal transplant patients. Transplantation, 2000,
69:S260.
Lewis PJ, Babiuk L A. DNA vaccines: A review. Adv Virus Res,
1999, 54:129–188.
Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade
plus rapamycin but not cyclosporine produces permanent
engraftment. Transplantation, 1998, 66:1387–1388.
Lo Iacono O, Castro A, Diago M, et al. Interferon alfa-2b plus
ribavirin for chronic hepatitis C patients who have not
responded to interferon monotherapy. Aliment Pharmacol
Ther, 2000, 14:463–469.
Mariat C, Alamartine E, Diab N, et al. Randomized prospective
study comparing low-dose OKT3 to low-dose ATG for the
treatment of acute steroid-resistant rejection episodes in kidney
transplant recipients. Transplant Int, 1998, 11:231–236.
Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and
fluorouracil for adjuvant therapy of resected colon carcinoma.
N Engl J Med, 1990, 322:352–358.
Monaco AP. A new look at polyclonal antilymphocyte antibodies
in clinical transplantation. Graft, 1999, 2:S2–S5.
Moltó A, Olivé A. Anti-IL-1 molecules: New comers and new
indications. Joint Bone Spine, 2010, 77:102–107.
Murphy B, Krensky AM. HLA-derived peptides as novel
immunomodulatory therapeutics. J Am Soc Nephrol, 1999,
10:1346–1355.
Nakakura EK, Shorthouse RA, Zheng B, et al. Long-term
survival of solid organ allografts by brief anti-lymphocyte
function-associated antigen-1 monoclonal antibody monotherapy.
Transplantation, 1996, 62:547–552.
Nankivel BJ, Borrows RJ, Fung CL, et al. The natural history of
chronic allograft nephropathy. N Engl J Med, 2003, 349:
2326–2333.
Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic
properties, clinical efficacy and tolerability of a
microemulsion-based formulation (Neoral). Drugs, 1995, 50:
924–941.
Opelz G, Terasaki PI. Improvement of kidney-graft survival with
increased numbers of blood transfusions. N Engl J Med, 1978,
299:799–803.